Charles Cherington - 27 Dec 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CMRA	12.0% Senior Secured Convertible Notes	Purchase	$567,900			$567,900	29 Dec 2023	Common Stock	10,325,454	$0.0550	Direct	F1
transaction	CMRA	Warrants to Purchase Common Stock	Purchase	$0	+20,650,908	$0.000000	20,650,908	29 Dec 2023	Common Stock	20,650,908	$0.0550	Direct	F1
transaction	CMRA	Series A Convertible Perpetual Preferred Stock	Purchase	$1,947,765,000	+3,896	$500000.00^*	3,896	27 Dec 2023	Common Stock	310,153	$12.56	By LLC	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof.
F2	The preferred stock was acquired by Comera SPV LLC ("SPV") in a private transaction pursuant to a purchase agreement, dated as of December 27, 2023, with an unaffiliated, institutional investor.
F3	The preferred stock is perpetual and therefore has no expiration date.
F4	The reporting person is the General Partner of SPV. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.